



Press Release

Tuesday, May 05, 2009

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE : 532531

NSE : STAR

STRIDES ARCOLAB COMMENCES COMMERCIAL SUPPLIES OF OSELTAMIVIR CAPSULES FOR Influenza-A(H1N1) VIRUS (SWINE FLU)

Strides Arcolab, a leading Indian pharma company today announced commencement of commercial supplies of Oseltamivir capsules to various countries.

Strides is one of the few approved manufacturers in India of this product – the generic equivalent of Tamiflu[®] - Roche's innovator product.

At present, limited stocks of Oseltamivir are available but the company is gearing up capacities to produce in excess of 2 million doses per month starting June 2009.

Strides' generic Oseltamivir is manufactured in its US FDA approved and WHO pre-qualified oral dosage forms manufacturing facility in Bangalore; bio-equivalence to Tamiflu has been established.

Ms. Aloka Sengupta, President – Business Development India Operations stated “We are particularly well equipped to handle such emergencies as we specialize in manufacture and supply of products that are used to treat similar disease epidemics”

Strides Overview

Strides, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a Bangalore, India head quartered global pharmaceutical company. Strides manufactures pharmaceutical formulations in various dosage forms, including sterile injectables with dedicated facilities for Penicillin and Penems, Cephalosporins, Oncolytics and lyophilized injectable products. The company also manufactures pharmaceutical formulations in oral dosage forms, including capsules & tablets and softgel capsules. Strides operate in and has significant presence in Australia, Africa and India and through a series of strategies is expanding its North

American and European growth. The company has series of joint ventures and front-ended operations in major markets and is a majority stakeholder of Ascent Pharmahealth Limited (APH), an ASX listed company. The company also collaborates closely with Global Drug Agencies and US-PEPFAR and the UNICEF to supply a range of affordable generic pharmaceutical products used in the treatment of HIV, TB and Malaria.

Strides also has a collaboration agreement with Aspen Pharmacare involving a range of products and territories including a Joint Venture in the Oncolytics space in Bangalore. Recently, the JV concluded a significant transaction with GSK to outlicence products for GSK's emerging market strategies in over 95 countries

Strides has manufacturing facilities in Bangalore, India and overseas facilities in Milan, Warsaw, Singapore and Lagos. The Indian manufacturing facilities are approved by all major regulatory bodies, Strides employs approximately 2500 people across the globe. Strides also has a marketing presence in over 50 countries.

Additional information about Strides is available at the company's website www.stridesarco.com

<p>For further information, please contact:</p> <p><i>For products information:</i></p> <p>Ms. Aloka Sengupta President – Business Development India Operations Ph: +91 80 6658 0748 Email: aloka.sengupta@stridesarco.com</p> <p><i>For Company information:</i></p> <p>Mr. Kannan N Company Secretary Ph: +91 80 6658 0751 Email: kannan.n@stridesarco.com</p>	<p>Mr. Mahesh Nair Corporate Voice Weber Shandwick Mob: +91 98803 76648 Email: maheshn@corvoshandwick.co.in</p> <p>Ms. Kasturi Wasmatar Voice Weber Shandwick Mob: +91 99167 28393 Email: kasturi@corvoshandwick.co.in</p>
---	--